BRAF and malignant colon neoplasm: These findings led us to explore the role of sphingolipid metabolism in the development of resistance to vemurafenib in BRAF mutant colon cancer cells and to investigate the possibility of targeting sphingolipid metabolic regulators to counteract vemurafenib resistance.